Eli Lilly (LLY)

Novo Nordisk could maintain this latest early-mover advantage longer than you think.

Micron has had a turnaround for the ages, going from a free cash flow negative company to a $1 trillion valuation in a little over a year.

Eli Lilly just announced a trio of acquisitions that will allow it to build a new business focused on infectious diseases.

Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable.

International growth could help push Lilly even higher.

Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake.

The stock market appears to be rotating into health care.

One fund backs medical breakthroughs and charity, while the other favors industry giants and steady income. Compare their strategies and portfolio makeup.

Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.

It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market.

What Happened? Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 6.3% in the afternoon session after the company announced its Weight Wat...

AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during a company presentation focused on the biotech’s pipeline and lead clinical program. Booth said

Broadcom’s weak AI-chip guidance rattled semiconductors and raised questions about tech valuations today, June 4, 2026.

Weight Watchers joins LillyDirect for GLP-1 access as Eli Lilly signs a kidney disease research pact with Ascidian worth up to $1.9 billion.

Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare.

The shares are up more than 13% this year, and the pharmaceutical company has several other factors that could drive its stock higher.

Eli Lilly is far from a one-trick pony.

Sen. Elizabeth Warren questioned Trump's trading activity, citing potential conflicts of interest and renewing calls for a stock-trading ban.

The most recent research report on the "Avascular Necrosis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts,

Can any company pose a serious challenge to Eli Lilly in the weight-loss market?

There is light at the end of the tunnel.

SpaceX looks like a rocket, but don't fly too close to the sun. Here's why Eli Lilly is likely a better stock to own.

This particular sector may suit cautious and aggressive investors.